Pharmacology of antiepileptic drugs in clinical practice

Neurologist

Volumn 16, Issue 6, 2010, Pages 353-357

  Guimarães, Joana ^a,b   Ribeiro, José Augusto Mendes ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Antiepileptic drugs; epilepsy management; pharmacology

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPIN 2 ONE DERIVATIVE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED SODIUM CHANNEL; ZONISAMIDE;

ADVERSE OUTCOME; ANTICONVULSANT ACTIVITY; CLINICAL PRACTICE; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG UPTAKE; EPILEPSY; GABAERGIC SYSTEM; HUMAN; KNOWLEDGE; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY;

ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; SEIZURES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 78650841901     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181dba5d3     Document Type: Review

References (32)

1. Sander JWAS. Some aspects of prognosis in the epilepsies: A review. Epilepsia. 1993;34:1007-1016.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;242:314-319.
3. Mcdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia. 1995;36:S2-S12.
4. Meldrum BS. Update on the mechanism of action of antiepileptic drug. Epilepsia. 1999;37:S4-S11.
5. Chadwick D. Zonisamide: Chemistry, Mechanism of Action, and Pharmacokinetics. NJ: Clinicians Group; 2001.
6. McAuley JW, Biederman TS, Smith JC, et al. Newer therapies in the drug treatment of epilepsy. Ann Pharmacother. 2002;36: 119-129.
7. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999;40:1471-1483.
8. Shorvon S. Handbook of Epilepsy Treatment. MA: Blackwell Science; 2000.
9. Wyllie E. The Treatment of Epilepsy: Principles and Practice. Baltimore, MD: Lippincott Williams & Wilkins; 1997.
10. Vreugdenhil M, Wadman WJ. Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia. 1999;40:1512-1522.
11. Cosford ND, Meinke PT, Stauderman KA, et al. Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy. Curr Drug Targets CNS Neurol Disord. 2002;1: 81-104.
12. Yogeeswari P, Ragavendran JV, Thirumurugan R, et al. Ion channels as important targets for antiepileptic drug design. Curr Drug Targets. 2004;5:589-602.
13. Armijo JA, de las Cuevas I, Adín J. Ion channels and epilepsy. Rev Neurol. 2000;30(suppl 1):S25-S41.
14. Davies A, Hendrich J, Van Minh AT, et al. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol Sci. 2007;28:220-228. Epub 2007 Apr 2.
15. Petroff OA, Hyder F, Rothman DL, et al. Brain homocarnosine and seizure control of patients taking gabapentin or topiramate. Epilepsia. 2006;47:495-498.
16. Bouwman BM, Suffczynski P, Lopes da Silva FH, et al. GABAergic mechanisms in absence epilepsy: A computational model of absence epilepsy simulating spike and wave discharges after vigabatrin in WAG/Rij rats. Eur J Neurosci. 2007;25:2783-2790.
17. Tolmacheva EA, van Luijtelaar G. Absence seizures are reduced by the enhancement of GABA-ergic inhibition in the hippocampus in WAG/Rij rats. Neurosci Lett. 2007;416:17-21.
18. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther. 2007;113:165-183.
19. Meador KJ, Loring DW, Hulihan JF, et al; CAPSS-027 Study Group. Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 2003;60:1483-1488.
20. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med. 1996;334:168-175.
21. Brodie MJ, Kwan P. The star systems: Overview and use in determining antiepileptic drug choice. CNS Drugs. 2001;15:1-12.
22. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the new antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
23. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101: 9861-9866.
24. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed. Epilepsia. 2000;41:1364-1374.
25. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094-1120.
26. Knaw P, Brodie J. Epilepsy after the first drug fails: Substitution or add-on? Seizure. 2000;9:464-468.
27. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology. 2002;58(suppl 5):S2-S8.
28. Somerville ER. Seizure aggravation by antiepileptic drugs. Curr Treat Options Neurol. 2006;8:289-296.
29. Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol. 2005;33:227-234.
30. Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia. 2007;48:2111-2115.
31. Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90: 21-34.
32. Birbeck GL, Hays RD, Cui X, et al. Seizure reduction and quality of life improvements in people with epilepsy. Epilepsia. 2002;43: 535-538.